|
1.
|
|
30 p, 7.5 MB |
The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer
/
De Mattos-Arruda, Leticia (Vall d'Hebron Institut d'Oncologia) ;
Sammut, S.J. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ;
Ross, E.M. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ;
Bashford-Rogers, R. (Department of Medicine. University of Cambridge) ;
Greenstein, E. (Department of Immunology. Weizmann Institute of Science) ;
Markus, H. (Mayo Clinic Center for Individualized Medicine) ;
Morganella, S. (Department of Medical Genetics. The Clinical School. University of Cambridge) ;
Teng, Y. (Cancer Molecular Diagnosis Laboratory. NIHR Cambridge Biomedical Research Centre) ;
Maruvka, Y. (Massachusetts General Hospital Cancer Center and Department of Pathology) ;
Pereira, B. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ;
Rueda, O.M. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ;
Chin, S.F. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ;
Contente-Cuomo, T. (Mayo Clinic Center for Individualized Medicine) ;
Mayor, R. (Spanish Biomedical Research Network Centre in Oncology (CIBERONC)) ;
Arias, Alexandra (Vall d'Hebron Institut d'Oncologia) ;
Ali, H.R. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ;
Cope, W. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ;
Tiezzi, D. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ;
Dariush, A. (Institute of Astronomy. University of Cambridge) ;
Dias Amarante, T. (Department of Medical Genetics. The Clinical School. University of Cambridge) ;
Reshef, D. (Department of Immunology. Weizmann Institute of Science) ;
Ciriaco, 0000-0002-1151-554X (Hospital Universitari Vall d'Hebron) ;
Martinez-Saez, Elena (Hospital Universitari Vall d'Hebron) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Cortes, Javier (Vall d'Hebron Institut d'Oncologia) ;
Vassiliou, G. (Wellcome Trust/MRC Cambridge Stem Cell Institute) ;
Getz, G. (Massachusetts General Hospital Cancer Center and Department of Pathology) ;
Nik-Zainal, S. (Department of Medical Genetics. The Clinical School. University of Cambridge) ;
Murtaza, M. (Mayo Clinic Center for Individualized Medicine) ;
Friedman, N. (Department of Immunology. Weizmann Institute of Science) ;
Markowetz, F. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ;
Seoane Suárez, Joan (Vall d'Hebron Institut d'Oncologia) ;
Caldas, C. (Breast Cancer Programme. Cancer Research UK Cambridge Cancer Centre) ;
Universitat Autònoma de Barcelona
The detailed molecular characterization of lethal cancers is a prerequisite to understanding resistance to therapy and escape from cancer immunoediting. We performed extensive multi-platform profiling of multi-regional metastases in autopsies from 10 patients with therapy-resistant breast cancer. [...]
2019 -  10.1016/j.celrep.2019.04.098
Cell reports, Vol. 27 Núm. 9 (28 2019) , p. 2690-2708.e10
|
|
|
2.
|
|
14 p, 4.6 MB |
Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases
/
De Mattos-Arruda, Leticia (Department of Pathology, Memorial Sloan Kettering Cancer Center) ;
Ng, Charlotte K. Y. (Department of Biomedicine, University of Basel, Basel, Switzerland) ;
Piscuoglio, Salvatore (Institute of Pathology, University Hospital Basel) ;
Gonzalez-Cao, Maria (Hospital Universitari Quirón Dexeus) ;
Lim, Raymond S. (Department of Pathology, Memorial Sloan Kettering Cancer Center) ;
De Filippo, Maria R. (Department of Pathology, Memorial Sloan Kettering Cancer Center) ;
Fusco, Nicola (Department of Pathology, Memorial Sloan Kettering Cancer Center) ;
Schultheis, Anne M. (Department of Pathology, Memorial Sloan Kettering Cancer Center) ;
Ortiz, Carolina (Vall d'Hebron Institut d'Oncologia) ;
Viteri, Santiago (Hospital Universitari Quirón Dexeus) ;
Arias, Alexandra (Vall d'Hebron Institut d'Oncologia) ;
Macedo, Gabriel S. (Department of Pathology, Memorial Sloan Kettering Cancer Center) ;
Oliveira, Mafalda (Vall d'Hebron Institut d'Oncologia) ;
Gomez, Patricia (Vall d'Hebron Institut d'Oncologia) ;
Teixidó, Cristina (Hospital Universitari Quirón Dexeus) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Saura, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Tresserra Casas, Francesc (Hospital Universitari Quirón Dexeus) ;
Weigelt, Britta (Department of Pathology, Memorial Sloan Kettering Cancer Center) ;
Cortes, Javier (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Seoane Suárez, Joan (Institució Catalana de Recerca i Estudis Avançats (ICREA)) ;
Reis-Filho, Jorge S. (Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center)
Brain metastases constitute a challenge in the management of patients with HER2-positive breast cancer treated with anti-HER2 systemic therapies. Here we sought to define the repertoire of mutations private to or enriched for in HER2-positive brain metastases. [...]
2018 - 10.18632/oncotarget.25041
Oncotarget, Vol. 9 (april 2018) , p. 20617-20630
|
|
|
3.
|
|
8 p, 500.8 KB |
Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer
/
Gueorguieva, Ivelina (Eli Lilly and Company (United Kingdom)) ;
Cleverly, Ann (Eli Lilly and Company (United Kingdom)) ;
Desaiah, Durisala (Eli Lilly and Company (USA)) ;
Azaro, Analía (Hospital Universitari Vall d'Hebron) ;
Seoane Suárez, Joan (Vall d'Hebron Institut d'Oncologia) ;
Braña, Irene (Hospital Universitari Vall d'Hebron) ;
Sicart, Elisabet (Hospital Universitari Vall d'Hebron) ;
Miles, Colin (Eli Lilly and Company (United Kingdom)) ;
Lahn, Michael M (Eli Lilly and Company (USA)) ;
Mitchell, Malcolm I (Eli Lilly and Company (USA)) ;
Rodón Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
Galunisertib (LY2157299 monohydrate), an inhibitor of the transforming growth factor β (TGFβ) pathway, is currently under investigation in several clinical trials involving multiple tumor types. The primary objective of this study was to assess relative bioavailability of two new galunisertib formulations developed using the roller compaction (RC) dry-milled (RCD) and RC slurry-milled (RCS) processes, compared with the existing formulation developed using the high-sheer wet granulation (HSWG) process. [...]
2016 - 10.7573/dic.212303
Drugs in Context, Vol. 5 (December 2016) , art. 201303
|
|
|
4.
|
|
12 p, 2.2 MB |
MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients
/
De Mattos-Arruda, Leticia (Vall d'Hebron Institut d'Oncologia) ;
Bottai, Giulia (Oncology Experimental Therapeutics Unit. IRCCS Humanitas Clinical and Research Institute (Italy)) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Di Tommaso, Luca (Division of Pathology. IRCCS Humanitas Clinical and Research Institute (Italy)) ;
Giovannetti, Elisa (University of Pisa. Cancer Pharmacology Laboratory. AIRC Start-Up Unit (Italy)) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron) ;
Losurdo, Agnese (Division of Oncology and Hematology. IRCCS Humanitas Clinical and Research Institute (Italy)) ;
Pérez-Garcia, José (Vall d'Hebron Institut d'Oncologia) ;
Masci, Giovanna (Division of Oncology and Hematology. IRCCS Humanitas Clinical and Research Institute (Italy)) ;
Corsi, Fabio (University of Milan. Deparment of Clinical and Biomedical Sciences "Luigi Sacco" (Italy)) ;
Cortés, Javier (Hospital Universitario Ramón y Cajal) ;
Seoane Suárez, Joan (Vall d'Hebron Institut d'Oncologia) ;
Calin, George A. (The University of Texas MD Anderson Cancer Center (USA)) ;
Santarpia, Libero (Oncology Experimental Therapeutics Unit. IRCCS Humanitas Clinical and Research Institute (Italy)) ;
Universitat Autònoma de Barcelona
Patients with primary HER2-positive breast cancer benefit from HER2-targeted therapies. Nevertheless, a significant proportion of these patients die of disease progression due to mechanisms of drug resistance. [...]
2015 - 10.18632/oncotarget.5495
Oncotarget, Vol. 6, Num. 35 (October 2015) , p. 37269-37280
|
|
|
5.
|
|
11 p, 1.8 MB |
Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis
/
Annibali, Daniela (University of California) ;
Whitfield, Jonathan R. (Vall d'Hebron Institut d'Oncologia) ;
Favuzzi, Emilia (Università La Sapienza) ;
Jauset, Toni (Universitat Autònoma de Barcelona) ;
Serrano, Erika (Universitat Autònoma de Barcelona) ;
Cuartas, Isabel (Universitat Autònoma de Barcelona) ;
Redondo Campos, Sara (Universitat Autònoma de Barcelona) ;
Folch, Gerard (Universitat Autònoma de Barcelona) ;
Gonzàlez Juncà, Alba (Universitat Autònoma de Barcelona) ;
Sodir, Nicole M. (University of Cambridge) ;
Massó Vallés, Daniel (Universitat Autònoma de Barcelona) ;
Beaulieu, Marie-Eve (Universitat Autònoma de Barcelona) ;
Swigart, Lamorna B. (University of California) ;
Mc Gee, Margaret M. (University College Dublin) ;
Somma, Maria Patrizia (Università La Sapienza) ;
Nasi, Sergio (Università La Sapienza) ;
Seoane Suárez, Joan (Institució Catalana de Recerca i Estudis Avançats (ICREA)) ;
Evan, Gerard I. (University of Cambridge) ;
Soucek, Laura (Universitat Autònoma de Barcelona)
Gliomas are the most common primary tumours affecting the adult central nervous system and respond poorly to standard therapy. Myc is causally implicated in most human tumours and the majority of glioblastomas have elevated Myc levels. [...]
2014 - 10.1038/ncomms5632
Nature communications, Vol. 5 (August 2014) , art. 4632
|
|
|
6.
|
|
2 p, 149.6 KB |
Biòpsia líquida per a la identificació de tumors cerebrals de forma menys invasiva i més efectiva
/
Seoane Suárez, Joan
Departament de Bioquímica i de Biologia Molecular (Universitat Autònoma de Barcelona.)
La caracterització molecular dels tumors dels pacients i l'estudi de la seva evolució amb el temps són decisius pel correcte tractament del càncer. Tradicionalment, els tumors cerebrals s'han analitzat a partir d'una biòpsia de teixit, que suposa un risc pel pacient i no sempre permet accedir a una part representativa del tumor. [...]
La caracterización molecular de los tumores de los pacientes y el estudio de su evolución con el tiempo son decisivos para el correcto tratamiento del cáncer. Tradicionalmente, los tumores cerebrales se han analizado a partir de una biopsia de tejido, que supone un riesgo para el paciente y no siempre permite acceder a una parte representativa del tumor. [...]
The identification of each tumour type along with its respective individual molecular makeup is critical in tackling cancer with greater precision. To date, the analysis of brain tumours has consisted of a biopsy, which poses a risk in itself and does not necessarily facilitate access to a representative part of the tumour. [...]
2016
UAB divulga, Abril 2016
3 documentos
|
|
|
7.
|
|
2 p, 131.0 KB |
Demostren l'efectivitat d'un fàrmac contra les cèl·lules que inicien els tumors
/
Seoane Suárez, Joan (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Un estudi dirigit pel professor de la UAB Joan Seoane, investigador principal del grup de recerca Expressió Gènica i Càncer del Vall d'Hebron Institut d'Oncologia (VHIO), ha identificat marcadors que assenyalen quines són les cèl·lules responsables de l'inici i recurrència d'un tumor. [...]
Un estudio dirigido por el profesor de la UAB Joan Seoane, investigador principal del grupo de investigación Expresión Génica y Cáncer del Vall d'Hebron Institut d'Oncologia (VHIO), ha identificado marcadores que señalan cuáles son las células responsables del inicio y recurrencia de un tumor. [...]
A research carried out by Joan Seoane, head researcher of the Gene Expression and Cancer group at Vall d'Hebron Institute of Oncology (VHIO), identified markers indicating the cells responsible for the onset and recurrence of tumours. [...]
2010
UAB divulga, Desembre 2010, p. 1-2
3 documentos
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
